Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunovant (IMVT) Cash from Financing Activities (2019 - 2026)

Immunovant filings provide 7 years of Cash from Financing Activities readings, the most recent being $564.6 million for Q4 2025.

  • Quarterly Cash from Financing Activities rose 22814.08% to $564.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.0 billion through Dec 2025, up 19120.79% year-over-year, with the annual reading at $454.5 million for FY2025, 3.8% down from the prior year.
  • Cash from Financing Activities hit $564.6 million in Q4 2025 for Immunovant, up from $24.6 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $564.6 million in Q4 2025 and bottomed at $21000.0 in Q2 2022.
  • Average Cash from Financing Activities over 5 years is $105.3 million, with a median of $1.5 million recorded in 2024.
  • The largest annual shift saw Cash from Financing Activities tumbled 99.95% in 2021 before it skyrocketed 29065.83% in 2025.
  • Immunovant's Cash from Financing Activities stood at $200.0 million in 2021, then crashed by 64.69% to $70.6 million in 2022, then surged by 565.21% to $469.8 million in 2023, then plummeted by 99.48% to $2.5 million in 2024, then surged by 22814.08% to $564.6 million in 2025.
  • Per Business Quant, the three most recent readings for IMVT's Cash from Financing Activities are $564.6 million (Q4 2025), $24.6 million (Q3 2025), and $2.9 million (Q2 2025).